Ingrid Akay
Founder and Managing Partner @ Hadean Ventures
Oslo, Norway
Ingrid Akay is a Series A investor at Hadean Ventures in Oslo focused on Medical and Biotechnology. Ingrid Teigland Akay is based out of Oslo, Oslo, and is the founder and managing partner of Hadean Ventures. Ingrid previously worked at Neuro Event Labs as a board member. Ingrid Teigland Akay attended the London Business School. Ingrid Teigland Akay has received the Investor of the Year award.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Ingrid Akay invests in
Stages Ingrid Akay invests in
Countries Ingrid Akay invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 3 (43%)
- Biotechnology 3 (43%)
- Health Care 2 (29%)
- Chemical 1 (14%)
- Genetics 1 (14%)
Stage
- Series A 2 (29%)
- Venture - Series Unknown 2 (29%)
- Funding Round 1 (14%)
Country
- Norway 2 (29%)
- Sweden 2 (29%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Alex Therapeutics, a digital therapeutics company, is changing the way clinicians provide support for patients to change unwanted habits leading to poor medical outcomes. Our proprietary AI-platform is used as the basis when we develop CE-marked software medical devices (Class I) apps for a variety of therapeutic areas. | $5.1M / Venture - Series Unknown / Mar 03, 2023 | ||
| Alex Therapeutics, a digital therapeutics company, is changing the way clinicians provide support for patients to change unwanted habits leading to poor medical outcomes. Our proprietary AI-platform is used as the basis when we develop CE-marked software medical devices (Class I) apps for a variety of therapeutic areas. | $3.8M / Apr 06, 2022 | ||
| Alex Therapeutics, a digital therapeutics company, is changing the way clinicians provide support for patients to change unwanted habits leading to poor medical outcomes. Our proprietary AI-platform is used as the basis when we develop CE-marked software medical devices (Class I) apps for a variety of therapeutic areas. | $3.8M / Venture - Series Unknown / Apr 06, 2022 | ||
| Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns. | $29.2M / Venture - Series Unknown / Jun 29, 2021 | ||
| CardioMech is a developer of therapeutic devices for structural heart disease that provides a transcatheter alternative to cardiac surgery for the placement of artificial chords for the mitral valve. The company's devices are used for the placement of artificial chords, enabling surgeons to get access to new therapeutic options for heartdiseases. The technology is being developed to treat patients with severe, symptomatic, degenerative mitral regurgitation (DMR) due to prolapse or flail.CardioMech was founded in 2015 and is headquartered in Trondheim, Norway. | $18.5M / Series A / Aug 05, 2020 | ||
| Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns. | $6M / Venture - Series Unknown / May 19, 2020 | ||
| SAGA Diagnostics AB is a personalized cancer diagnostics and disease monitoring company focused on molecular genetic analyses of a powerful cancer biomarker: circulating tumor DNA (ctDNA). The company was founded in 2016 as a spin-out from a highly successful research group at Lund University, with a mission to improve precision cancer medicine,provide more accurate treatment monitoring, and improve patient survival using minimally-invasive liquid biopsy cancer testing services and kits.The SAGA team consists of renowned scientists, highly qualified staff and an experienced management team who work together to launch SAGA’s ultrasensitive services and products as part of the ongoing revolution in cancer research, drug development, and clinical diagnostics. SAGA’s proprietary tests can help patients, oncologists, and drug developers detect actionable mutations, stratify patient groups, and monitor treatment response, residual disease, and disease recurrence at an unprecedented sensitivity. | $4.2M / Series A / Jun 11, 2019 |
Co-Investors
About Hadean Ventures
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Hadean Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Florian Eckhardt
Senior Investment Director
|
|||
|
Ingrid Akay
Founder and Managing Partner
|
|||
Ingrid Beyer
Head of Investor Relations
|
|||
Roger Franklin
Partner
|
|||
Walter Stockinger
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ingrid Akay invest in?
Ingrid Akay invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 7 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ingrid Akay?
Public channels for Ingrid Akay include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ingrid Akay last invest?
The most recent investment recorded for Ingrid Akay closed in Mar 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
